All In Biotech

Drug Trial Radar · NCT01965912

Kuvan®'s Effect on the Cognition of Children With Phenylketonuria

A Phase 4 Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children With Phenylketonuria Treated With Sapropterin Dihydrochloride (Kuvan®) for 7 Years

Last checked: Nov 20, 2026Latest source record: Apr 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Oct 2013

Primary completion

Jan 4, 2023

Study completion Jan 4, 2023

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Oct 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a single-cohort, interventional, open-label trial to evaluate long-term neurocognitive (NC) outcomes in children aged 4 to 5 years with phenylketonuria (PKU) treated with Kuvan® and Phenylalanine-restricted diet over a period of 7 years.

Conditions

  • Phenylketonuria

Interventions

  • Kuvan®Drug

    Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Full Scale Intelligence Quotient (FSIQ) Score of the Wechsler Intelligence Scale for Children (WISC)-IVTime frame: Year 7

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • Research site

    Munich, Germany

  • Research site

    Münster, Germany

  • Research site

    Bologna, Italy

  • Research site - Bambino Gesu

    Roma, Italy

  • Research site - La Sapienza

    Roma, Italy

  • Research Site

    Barcelona, Spain

  • Research site

    Murcia, Spain

  • Research site

    Santiago de Compostela, Spain

  • Research site

    Birmingham, United Kingdom

  • Research site

    Bristol, United Kingdom

  • Research Site - Evelina

    London, United Kingdom

  • Research site - GOSH

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.